South Dakota Investment Council lifted its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 1.8% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 156,030 shares of the insurance provider's stock after buying an additional 2,713 shares during the quarter. Humana makes up 0.8% of South Dakota Investment Council's holdings, making the stock its 14th largest holding. South Dakota Investment Council owned 0.13% of Humana worth $41,286,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of HUM. Achmea Investment Management B.V. boosted its holdings in shares of Humana by 0.5% in the 1st quarter. Achmea Investment Management B.V. now owns 10,379 shares of the insurance provider's stock valued at $2,746,000 after buying an additional 49 shares in the last quarter. Beech Hill Advisors Inc. raised its position in shares of Humana by 6.1% during the 1st quarter. Beech Hill Advisors Inc. now owns 865 shares of the insurance provider's stock worth $229,000 after purchasing an additional 50 shares during the last quarter. Deseret Mutual Benefit Administrators raised its position in shares of Humana by 15.8% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 462 shares of the insurance provider's stock worth $122,000 after purchasing an additional 63 shares during the last quarter. Vise Technologies Inc. boosted its position in shares of Humana by 8.0% during the 4th quarter. Vise Technologies Inc. now owns 873 shares of the insurance provider's stock valued at $221,000 after acquiring an additional 65 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in shares of Humana by 17.1% in the 1st quarter. Versant Capital Management Inc now owns 453 shares of the insurance provider's stock valued at $120,000 after buying an additional 66 shares during the period. Hedge funds and other institutional investors own 92.38% of the company's stock.
Humana Price Performance
Shares of NYSE:HUM traded up $3.93 on Monday, reaching $224.34. The company's stock had a trading volume of 1,159,434 shares, compared to its average volume of 1,822,628. The company has a 50-day simple moving average of $234.87 and a 200 day simple moving average of $257.29. The company has a market cap of $27.08 billion, a P/E ratio of 15.87, a PEG ratio of 1.51 and a beta of 0.44. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.91 and a current ratio of 1.91. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $406.09.
Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. The business's revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $7.23 earnings per share. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on HUM shares. Bank of America decreased their price target on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a report on Tuesday, June 17th. Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a research note on Thursday, May 1st. Guggenheim assumed coverage on shares of Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price objective for the company. Truist Financial decreased their price objective on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Finally, Oppenheimer upped their price target on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research report on Thursday, May 1st. Sixteen research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Humana has an average rating of "Hold" and a consensus target price of $282.57.
Check Out Our Latest Report on HUM
Humana Company Profile
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
